【产品介绍】：

生物活性：Regorafenib-13C,d3 is the 13C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[89].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Regorafenib-13C,d3 相关抗体:
BRAF Antibody
Phospho-BRAF (Thr401) Antibody
A-RAF Antibody
B-Raf Antibody
Phospho-PDGFR beta (Y740) Antibody
VEGF Receptor 2 Antibody (YA014)
PDGFR alpha Antibody
Raf1 Antibody
VEGF Receptor 1 Antibody
VEGFA Antibody
VEGF Receptor2 Antibody
PDGF B Antibody (YA1556)
PLGF Antibody (YA1812)
RKIP Antibody (YA1869)
PDGFR beta Antibody (YA1925)
VEGFD Antibody (YA2385)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
VEGFB Antibody (YA2627)
A RAF Antibody (YA2673)
分子量：486.83
Formula：C2013CH12D3ClF4N4O3
非标记 CAS：755037-03-7
中文名称：瑞戈非尼-13C,d3；瑞格非尼-13C,d3；瑞格菲尼-13C,d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (527 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.
 [Content Brief]
[3]. Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2(1), 39-49.
 [Content Brief]
[4]. Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.
 [Content Brief]
[5]. Wagner J, et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018 Jan 22;37(1):11.
 [Content Brief]
[6]. Matsuoka K, et al. Effective Sequential Combined Chemotherapy with Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018 Sep 25;19(10). pii: E2915.
 [Content Brief]